Abstract
These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Current Pharmaceutical Design
Title:Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya
Volume: 19 Issue: 26
Author(s): Anjali Soni, Khushhali M. Pandey, Pratima Ray and B. Jayaram
Affiliation:
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Abstract: These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Export Options
About this article
Cite this article as:
Soni Anjali, Pandey M. Khushhali, Ray Pratima and Jayaram B., Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya, Current Pharmaceutical Design 2013; 19 (26) . https://dx.doi.org/10.2174/13816128113199990379
DOI https://dx.doi.org/10.2174/13816128113199990379 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets From ONYX-015 to Armed Vaccinia Viruses: The Education and Evolution of Oncolytic Virus Development
Current Cancer Drug Targets Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Dendritic Cells in Innate Immune Responses Against HIV
Current Molecular Medicine Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Hyperhomocysteinemia, Pteridines and Oxidative Stress
Current Drug Metabolism ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Crucial Protein Based Drug Targets and Potential Inhibitors for Osteoporosis: New Hope and Possibilities
Current Drug Targets Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease
Current Neuropharmacology Anionic Linear Globular Dendrimer-G2-Ciprofloxacin Nano-Conjugate: Novel Agent against Wilson Disease Cell Model
Letters in Drug Design & Discovery Importance of Fibroblasts-Myofibroblasts in Asthma-Induced Airway Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19
Current Pharmaceutical Design Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets Vascular Damage in Obesity and Diabetes: Highlighting Links Between Endothelial Dysfunction and Metabolic Disease in Zebrafish and Man
Current Vascular Pharmacology CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Sublingual Allergen Immunotherapy: Immunological Mechanisms and Prospects for Refined Vaccine Preparations
Current Medicinal Chemistry Mesenchymal Stromal Cells (MSCs): A Promising Tool for Cell-Based Angiogenic Therapy
Current Gene Therapy